Healthcare >> CEO Interviews >> January 27, 2003
RICHARD L. JACKSON is President and Chief Executive Officer of
EmerGen, Inc. He joined the company in March 2001. Prior to
becoming an executive at EmerGen, Dr. Jackson held senior
research and development positions at Wyeth, Atrix Laboratories
and Marion Merrel Dow. Dr. Jackson served as Senior Vice
President of Discovery Research at Wyeth and was instrumental in
establishing the company's Women's Health Institute. Under his
stewardship, more than 40 compounds moved into development, seven
of which are currently in clinical trials or have received FDA
approval. During his tenure at Atrix Laboratories as Senior Vice
President, Research and Development, Dr. Jackson helped raise $90
million for the company and submitted five products to the FDA,
one of which was recently approved. Dr. Jackson received his PhD
in Microbiology at the University of Illinois. He has had
academic appointments at the National Institutes of Health,
Baylor College of Medicine and the University of Cincinnati
Medical Center. Profile
Inc., and a picture of what you are doing at the present time?
Dr. Jackson: EmerGen, a start-up company founded in April
